High cholesterol is one of the biggest risk factors for heart disease, the leading cause of death worldwide.
When levels of low-density lipoprotein (LDL) cholesterol, often called “bad” cholesterol, become too high, fatty deposits can build up inside blood vessels. Over time, these deposits can narrow the arteries and increase the risk of heart attacks, strokes, and other serious cardiovascular problems.
To lower LDL cholesterol and protect the heart, doctors often prescribe medications known as statins. Among the most commonly used statins are rosuvastatin and atorvastatin.
Both drugs have been used for many years and are known to effectively reduce cholesterol levels. However, researchers have continued to debate whether one drug may offer better protection or fewer side effects than the other.
A large clinical trial called LODESTAR has now provided new information that may help answer this question. The study compared rosuvastatin and atorvastatin in people with coronary artery disease, a condition in which plaque builds up inside the arteries that supply blood to the heart.
Coronary artery disease is one of the most common forms of heart disease. It can reduce blood flow to the heart muscle and increase the risk of chest pain, heart attacks, heart failure, and sudden cardiac death. Because lowering cholesterol is a key part of treatment, choosing the most appropriate statin is an important decision for both doctors and patients.
The LODESTAR study included 4,400 adults diagnosed with coronary artery disease. Participants were randomly assigned to receive either rosuvastatin or atorvastatin. The researchers followed them for approximately three years between 2016 and 2019 to evaluate how well each medication protected against serious cardiovascular events.
The primary goal was to compare major outcomes such as heart attacks, strokes, death, and procedures used to reopen blocked arteries.
When the researchers analyzed the results, they found that both medications performed very similarly. There were no significant differences between the rosuvastatin and atorvastatin groups in terms of heart attacks, strokes, deaths, or the need for artery-opening procedures.
In other words, both drugs appeared equally effective at reducing the risk of major cardiovascular events in people with coronary artery disease.
This finding is important because it suggests that doctors can confidently prescribe either medication when the primary goal is protecting patients from serious heart-related complications.
However, the study also uncovered some noteworthy differences.
Patients taking rosuvastatin achieved slightly lower LDL cholesterol levels compared with those taking atorvastatin. Since lower LDL cholesterol is generally associated with lower cardiovascular risk, this might initially seem like an advantage for rosuvastatin.
But the researchers also observed higher rates of certain side effects in the rosuvastatin group.
One of the most important findings was an increased risk of developing type 2 diabetes that required treatment with medication. Although statins have previously been linked to a small increase in diabetes risk, the study found that this risk was somewhat higher among people taking rosuvastatin.
The researchers also found a slightly higher rate of cataract surgery in the rosuvastatin group. Cataracts occur when the normally clear lens of the eye becomes cloudy, leading to blurred vision and, in some cases, requiring surgical treatment.
These findings highlight an important consideration in medical treatment. While lowering cholesterol is essential, choosing a medication also involves balancing potential benefits against possible risks.
The results suggest that rosuvastatin may offer somewhat greater cholesterol reduction but could also carry a slightly higher risk of certain side effects. Atorvastatin, on the other hand, may provide similar cardiovascular protection with somewhat lower rates of these particular complications.
The researchers emphasized that both medications remain effective and generally safe options for most patients. Rather than proving that one drug is clearly superior, the study suggests that treatment decisions should be individualized.
Factors such as a patient’s medical history, diabetes risk, eye health, cholesterol levels, and personal preferences may all play a role in determining which medication is most appropriate.
The study also has some limitations. All participants were of Asian ancestry, which means the findings may not fully apply to people from other ethnic backgrounds. In addition, the follow-up period lasted three years. Longer-term studies may provide additional information about the effects of these medications over time.
Despite these limitations, the research offers valuable guidance for healthcare providers and patients. It reinforces the idea that successful treatment is not simply about achieving the lowest cholesterol number possible. Instead, doctors must consider the whole person, including other health conditions and potential side effects.
Of course, medication is only one part of maintaining heart health. Lifestyle choices remain extremely important. Eating a balanced diet, exercising regularly, maintaining a healthy weight, controlling blood pressure, managing diabetes, and avoiding smoking can all help reduce cardiovascular risk.
For many people, the best results come from combining healthy lifestyle habits with appropriate medical treatment. Statins can play a powerful role in reducing heart disease risk, but they work best as part of a broader approach to health.
The findings from the LODESTAR study provide important new evidence that can help patients and doctors make more informed decisions about cholesterol-lowering treatment.
Both rosuvastatin and atorvastatin remain valuable tools in the fight against heart disease, but understanding their different strengths and potential risks can help ensure that each patient receives the treatment that best fits their needs.
If you care about heart disease, please read studies that herbal supplements could harm your heart rhythm, and how eating eggs can help reduce heart disease risk.
For more health information, please see recent studies that apple juice could benefit your heart health, and results showing yogurt may help lower the death risks in heart disease.
The study was published in the medical journal BMJ.
Copyright © 2026 Knowridge Science Report. All rights reserved.
